Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Parkinson’s Link to Gut Bacteria Suggests Unexpectedly Simple Treatment

Researchers have suspected for some time that the link between our gut and brain plays a role in the onset of Parkinson’s disease.

A recent study identified gut microbes likely to be involved and linked them with decreased riboflavin (vitamin B2) and biotin (vitamin B7), suggesting an unexpectedly simple treatment that may help: B vitamins.

“Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue for alleviating Parkinson’s symptoms and slowing disease progression,” said medical researcher Hiroshi Nishiwaki from Nagoya University in Japan, when the paper was published in May 2024.

Aged blood vessel cells drive metabolic diseases

Previous research by the investigators showed that eliminating senescent cells with drugs called senolytics improved metabolic function, the body’s method for turning food and drink into energy.

In the current study, investigators focused on senescent blood vessel cells. They selectively removed these cells from obese laboratory mice and found that the animals’ inflammation and fat mass were reduced—and blood sugar levels improved.

When the investigators transplanted senescent blood vessel cells into lean laboratory mice, those mice developed inflammation in fat tissue and metabolic dysfunction.

The lead said this occurred because senescent blood vessel cells release high levels of inflammatory molecules.

The investigators next treated both groups of mice with fisetin, a naturally occurring senolytic compound, and found that the mice had fewer senescent blood vessel cells and improved diabetic symptoms. Investigators saw a similar decline in senescent blood vessel cells when they treated tissue samples from obese human patients with fisetin.


Investigators found that aged blood vessel cells play a key role in the development of metabolic disorders, including diabetes. The preclinical findings, published in Cell Metabolism, could lead to new treatments for these complex disorders.

New Dementia Pill Clears First Major Safety Hurdle, Trial Reports

A new pill for treating dementia is delivering promising “topline” results in early-stage clinical trials, according to a recent press release by its makers.

The treatment, called VES001 after its developer Vesper Bio, is designed to tackle frontotemporal dementia (FTD) – the most common type of dementia in the under-60s.

In a two-part preliminary safety trial at two medical centres in the Netherlands and the UK, VES001 was given to people showing no signs of FTD, including six volunteers with an increased genetic risk for the condition.

/* */